INNOVATION - New biological medicine (approved by FDA in US) provides a new treatment option for patients with HER2-positive metastatic breast cancer who failed on multiple treatments.
De volgende infoavond vindt plaats op woensdagavond 6 november 2019
van 19u30 tot 21 u in het
UZ Gent - Zaal Stromboli route 1550 (13K12)
This program is in Dutch!
Grateful for a warm In*Team @hedera tonight! Kuddos to Celine Broeckaert, Tutti Passi, Rentree, Charlotte Benoot and Neliane for being such an awesome team again! Much love!
We are such big fans of this great book and its authors. Released just now!
An interesting position paper about the integration of cancer care issued by the European Cancer Organisation #ECCO.
Definitely worth the read!!
There has been some controversy recently related to a clinical study in The Netherlands comparing overall survival rates between women with BrCa1 and BrCa2 mutations who underwent preventive mastectomy and those who opted for regular screening. The results seem to suggest that for BrCa2 mutations, no clinically relevant differences exist. However, as with all clinical studies, the conclusions need to be put in context.
It was all about ‘Unleashing the potential of data to improve cancer care’ at the Oncology Data Summit organized by EFPIA today.